Endocannabinoid Regulation of Acute and Protracted Nicotine Withdrawal: Effect of FAAH Inhibition by Cippitelli, Andrea et al.
Endocannabinoid Regulation of Acute and Protracted















1School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy, 2Department of Pharmacology, University of California Irvine, Irvine, California, United
States of America, 3Department of Biomolecular Sciences, Medicinal Chemistry and Technology Unit, University of Urbino ‘‘Carlo Bo’’, Urbino, Italy, 4School of Pharmacy,
Medicinal Chemistry Unit, University of Camerino, Camerino, Italy, 5Fundacio ´n IMABIS, Hospital Carlos Haya de Ma ´laga, Malaga, Spain, 6Drug Discovery and
Development, Italian Institute of Technology, Genova, Italy
Abstract
Evidence shows that the endocannabinoid system modulates the addictive properties of nicotine. In the present study, we
hypothesized that spontaneous withdrawal resulting from removal of chronically implanted transdermal nicotine patches is
regulated by the endocannabinoid system. A 7-day nicotine dependence procedure (5.2 mg/rat/day) elicited occurrence of
reliable nicotine abstinence symptoms in Wistar rats. Somatic and affective withdrawal signs were observed at 16 and
34 hours following removal of nicotine patches, respectively. Further behavioral manifestations including decrease in
locomotor activity and increased weight gain also occurred during withdrawal. Expression of spontaneous nicotine
withdrawal was accompanied by fluctuation in levels of the endocannabinoid anandamide (AEA) in several brain structures
including the amygdala, the hippocampus, the hypothalamus and the prefrontal cortex. Conversely, levels of 2-
arachidonoyl-sn-glycerol were not significantly altered. Pharmacological inhibition of fatty acid amide hydrolase (FAAH), the
enzyme responsible for the intracellular degradation of AEA, by URB597 (0.1 and 0.3 mg/kg, i.p.), reduced withdrawal-
induced anxiety as assessed by the elevated plus maze test and the shock-probe defensive burying paradigm, but did not
prevent the occurrence of somatic signs. Together, the results indicate that pharmacological strategies aimed at enhancing
endocannabinoid signaling may offer therapeutic advantages to treat the negative affective state produced by nicotine
withdrawal, which is critical for the maintenance of tobacco use.
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Introduction
Nicotine is one of the most widely used addictive drugs, and
smoking tobacco is the most common form of substance abuse.
The World Health Organization (WHO) estimates that there are
1.25 billion smokers worldwide, representing one third of the
global population over the age of 15. Further estimates show that 5
million deaths occur each year as a direct result of tobacco use,
making nicotine abuse the largest single preventable cause of death
worldwide [1].
Nicotine, same as other abused drugs, has reinforcing psy-
choactive effects that lead to its self-administration. Although
positive reinforcement of nicotine is less effective than other
abused drugs [2], smoking cessation leads to an aversive state that
serves as a negative reinforcer to the maintenance of the tobacco
consumption in smokers [3,4,5]. Clinical studies have shown that
tobacco cessation leads to expression of withdrawal symptoms such
as irritability, anxiety, depressed mood, increased hunger,
restlessness, difficulty concentrating, sleep disturbances, weight
gain, decreased heart rate and craving for tobacco [6,7,8].
Emergence of negative withdrawal symptoms represent a primary
reason for the persistence of smoking and represent one of the
major obstacles for successful detoxification.
To shed light on nicotine withdrawal mechanisms several
animal models have been developed using rats [9,10,11,12,13] and
mice [14,15,16,17,18]. The rodent nicotine abstinence syndrome
is characterized by somatic manifestations and is accompanied by
aversive motivational and affective states. Such symptoms can
occur spontaneously after nicotine exposure cessation [11,19] or
can be precipitated by nicotinic acetylcholine receptor antagonists
[12,20] and reversed by further nicotine exposure [11]. This
evidence suggests that nicotinic receptors play a key role in the
neurobiology of nicotine withdrawal. However, nicotine affects the
function of several neurotransmitter systems, including dopamine,
opioid peptides, serotonin and glutamate systems [5,21]. Further-
more, functional interactions between nicotine and the endocan-
nabinoid systems in relation to addiction-related processes have
been described. Particularly, an overlapping distribution of
cannabinoid and nicotinic acetylcholine receptors was reported
in several brain areas including the hippocampus and the
amygdala [22]. Also, cannabinoid receptor activation has been
shown to modulate the release and turnover of acetylcholine in
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imental evidence indicates that these two systems facilitate each
other’s pharmacological and rewarding effects. For example, the
co-administration of subthreshold doses of delta-9-tetrahydrocan-
nabinol (D
9- THC), the main psychoactive ingredient in Cannabis,
and nicotine produced a significant conditioned place preference,
whereas nicotine rewarding effects were absent in cannabinoid
CB1 receptors knockout mice [26,27]. Consistently, the CB1
receptor antagonist rimonabant was shown to decrease nicotine
self-administration and conditioned place preference in rats [28,
29,30]. It was also shown that acute D
9-THC administration
significantly decreased the incidence of mecamylamine and
naloxone-precipitated nicotine withdrawal signs and ameliorated
the aversive motivational consequences of nicotine withdrawal in
mice [15,31].
Together these findings raise the question to whether expression
of nicotine withdrawal is associated with modifications in endo-
cannabinoid neurotransmission. Moreover, based on these data, it
would be relevant to evaluate whether pharmacological manipu-
lations of the endogenous cannabinoid system would affect
behaviors associated with the expression of nicotine abstinence
syndrome. To accomplish this objective, we generated a rat model
of spontaneous nicotine withdrawal following the removal of
chronically implanted transdermal nicotine patches and analyzed
the occurrence of ongoing somatic and affective (anxiety) with-
drawal signs. Next we evaluated tissue levels of the main endo-
cannabinoids, anandamide (arachidonoyl ethanol amide, AEA)
and 2-arachidonoyl-sn-glycerol (2-AG) during acute (16 hours) and
protracted (34 hours) nicotine withdrawal. The results show that
major changes occurred for AEA, while 2-AG was minimally
affected. Therefore, we used URB597, a potent and systemically
active inhibitor of fatty acid amido hydrolase (FAAH), the enzyme
responsible for AEA deactivation within cells [32,33,34], to




All experimental procedures were conducted in adherence to
the European Community Council Directive (86/609/CEE) and
the National Institutes of Health Guidelines for Care and Use of
Laboratory Animals. Authorization concerning the use of
laboratory animals and approval of experimental procedures was
provided by the Ministry of Health (Italy, de `cret 85/2007-A, 1
October, 2007).
Animals
Male Wistar rats (Charles River, Calco, Italy) weighting 275–
325 g at the beginning of the experiment were used. Animals were
housed in groups of two and kept on a reverse 12-h light/dark
cycle (lights on 20:00–08:00 h). Each experiment was conducted
with independent groups of rats during the dark phase of the cycle.
The following experimental groups were used: one batch of
animals (N=12; 6 nicotine-exposed and 6 non-exposed controls)
was used in Experiment 1 to evaluate the expression of somatic
and affective nicotine withdrawal signs at 16 and 34 hours from
patch removal, respectively. Another batch (N=27, Experiment 2)
was divided into two groups of 13 (8 nicotine and 5 vehicle) and 14
rats (8 nicotine and 6 vehicle) and was used to evaluate
extracellular concentration of AEA and 2-AG at 16 and 34 hours
following nicotine patches exposure. A third cohort of rats (N=32,
8 nicotine naı ¨ve vehicle treated; 8 nicotine-exposed vehicle
treated, 8 nicotine-exposed receiving URB597 0.1 mg/kg and 8
nicotine-exposed receiving URB597 0.3 mg/kg) was used in
Experiment 3 to evaluate the effects of FAAH inhibition on the
expression of somatic signs of withdrawal. Further animals (N=43,
10–11 per group, divided as in the Experiment 3) served to study
the effects of URB 597 on withdrawal-induced anxiety at
34 hours, as assessed in the elevated plus-maze (EPM, Experiment
4). In addition, other 27 (N=9/group) nicotine naı ¨ve rats were
used to test the anxiolytic effect of URB597 under basal condition.
Finally, others (N=31, 7–8 per group) were used in Experiment 5
to test at 34 hours the effects of the URB597 on anxiety-like
behavior assessed by the shock-probe defensive burying paradigm.
Additional Wistar rats (N=5) were used to determine the time
course of blood nicotine and cotinine levels during the dependence
induction procedure.
Drugs
Nicotine patches (NIQUITIN CQ Step 1, 21 mg/day, Glaxo,
Verona, Italy) were used for dependence induction. URB597 was
synthesized as previously described [35]. It was suspended in 5%
PEG400, 5%TWEEN-80 and 90% saline. The compound was
administered intraperitoneally (i.p.) at a volume of 1 ml/kg.
URB597 (0.1, 0.3 mg/kg) or vehicle was given 120 min prior the
signs’ observation and locomotor performance, since FAAH
inhibition by URB597 occurs rapidly (,15 minutes) and persists
more than six hours [34,36]. A 60 min pre-treatment time was
used prior to elevated plus-maze or shock-probe defensive burying
tests.
Dependence induction and withdrawal
Nicotine exposure - Rats were thoroughly shaved on the back,
depilated with a depilatory lotion and cleansed with water as
previously described [13]. Patches were divided into 4 equal parts
so that 5.2 mg/rat/day of nicotine was administered by patch
applied to the shaved region. Comparable doses were previously
shown to produce sufficiently high blood nicotine and cotinine
levels [37] to elicit occurrence of reliable nicotine abstinence
symptoms. Pieces of flexible fabric Band-Aid and waterproof tape
were used to wrap the nicotine patch to improve its adherence to
the rat’s back. Control rats were shaved and depilated, but only
the Band-Aid and waterproof tape were placed on their backs.
This application procedure was repeated for 7 consecutive days.
On day 8, transdermal patches were removed to study nicotine
withdrawal. Such experimental procedure was repeated through-
out all experiments.
Nicotine and cotinine blood level assessment - To determine
levels of nicotine and cotinine in the blood, rats were sacrificed at
the middle (4 days) and at the end (7 days) of the nicotine patch
application procedure. Two ml of trunk blood was collected and
then centrifuged at 4200 rpm at 17uC for 8 min. Following
collection of the supernatant quantitative analysis of samples was
determined by high performance liquid chromatography (HPLC)
coupled mass spectrometry (LC-MS). All samples were assessed in
triplicate. Nicotine and cotinine data are expressed as concentra-
tions in micrograms/liter (mg/l).
Assessment of somatic withdrawal signs - According with
previous studies showing that overt spontaneous nicotine with-
drawal signs appear 16 h after termination of nicotine exposure
and return toward baseline at 40 h [11,12], in the current
experiments we monitored physical abstinence signs 16 hours after
the removal of nicotine patches. The assessment of somatic signs
was performed by blind observation across 10 min. Observers
counted the frequency of signs on a standard checklist of nicotine
abstinence signs, as previously described [11]. The most frequently
observed categories included teeth-chattering/chews, writhes/
URB597 Suppresses Symptoms of Nicotine Withdrawal
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counted no more frequently than once per ten seconds.
Locomotor activity in the open field - At the same time as the
assessment of somatic withdrawal signs, locomotor activity was
recorded over a period of 10 min. Each rat was monitored for
locomotor activity while located in the open arena (MedAssociates,
St. Albans, VT). Interruptions of 10 equally spaced infrared light
beams recorded total distance traveled, immobility, vertical
movements, number of entries onto central zone of the arena
and time spent in this zone. These last two parameters were also
considered as a measure of anxiety. Activity was examined under
non-familiar dim-light conditions.
Weight - Changes in body weight are thought to measure
withdrawal intensity [38]. Animals were weighed each day when
transdermal patches were replaced. Additionally, body weights
were measured at the end of the exposure (T=0), at 16 (T=16)
and 34 (T=34) hours following patch removal.
Elevated Plus-Maze. Anxiety-like behavior was monitored
using a standard elevated plus-maze apparatus as previously
described [36,39]. The time spent in open arms and entries onto
open arms were used as measures of anxiety-like behavior. The
EPM test was carried out 34 h following removal of nicotine
patches. This time point corresponding to the late withdrawal
period [11] was chosen also based on the result of Experiment 1
showing increased anxiety in the nicotine-dependent group at this
time point.
Shock-probe defensive burying paradigm. The shock-
probe defensive burying test [40,41] was used as an additional
measure for the assessment of anxiety-like behavior. The defensive
burying apparatus was a modified home cage with 4 cm wood
chip bedding material evenly distributed throughout the cage. One
end of the cage contained a 0.75-cm hole through which a probe
delivering 1.5 mA electric shock upon contact was inserted into
the cage. The probe remained on throughout the test. Contacts to
probe resulted in the rat piling bedding material with treading-like
movements of the forepaws and shoveling movements of the head,
often directed toward the shock-probe. The latency to start
burying and duration of burying were used as a measure of
anxiety. The test was carried out 34 h following nicotine patch
removal under low light conditions. Each animal was used only
once.
Endocannabinoid levels in the brain
After 16 and 34 hours from patch removal, brains from animals
previously receiving nicotine and their respective controls were
removed and quickly frozen at 280uC until use. Brains were
dissected and tissue levels of AEA and 2-AG were measured in
discrete brain areas.
Chemical syntheses - Heptadecenoylethanolamide (HEA) was
prepared by the reaction of the heptadecenoyl chloride (Nu-Chek
Prep, Elysian, MN) with a 10-fold molar excess of ethanolamine
(Sigma-Aldrich, St. Luis, Missouri, USA). Reactions were con-
ducted in dichloromethane at 0–4uC for 15 min, with stirring. The
product was washed with water, dehydrated over sodium sulfate,
filtered, and dried under N2. It was identified by liquid chro-
matography/mass spectrometry (LC/MS) and
1H nuclear mag-
netic resonance spectroscopy. Purity was .98% by LC/MS.
Endocannabinoid extraction and analysis - Selected brain
regions were punched from the frozen brains using a cryo-cut
and cylindrical brain punchers (Fine Science tools, Foster City,
CA, USA), as previously described [42]. The location and length
of the punches were chosen based on a stereotaxic atlas [43].
Frozen punches were homogenized in 0.3 ml of methanol
containing HEA and 2-heptadecanoyl-sn-glycerol (Nu-Chek Prep,
Elysian, MN) as internal standards. Lipids were extracted with
chloroform (2 vol) and washed with water (1 vol). Protein
concentrations were measured using the BCA protein assay
(Pierce, Rockford, IL). Organic phases were collected and dried
under N2. Endocannabinoids were fractionated as described
previously [44]. Briefly, the lipids were reconstituted in chloroform
and loaded onto small glass columns packed with Silica Gel G (60-
A ˚ 230–400 Mesh ASTM; Whatman, Clifton, NJ). Endocannabi-
noids were eluted with 9:1 chloroform/methanol (vol/vol). Eluates
were dried under N2 and reconstituted in 0.1 ml of chloroform/
methanol (1:4, vol/vol) for LC/MS analyses.
LC/MS analyses - We used an 1100-LC system coupled to a
1946D-MS detector (Agilent Technologies, Inc., Palo Alto, CA)
equipped with an electrospray ionization interface. Endocannabi-
noids were separated using a XDB Eclipse C18 column
(5064.6 mm i.d., 1.8 mm, Zorbax), eluted with a gradient of
methanol in water (from 75% to 85% in 2.5 min and then to 90%
in 7.5 min) at a flow rate of 1.0 ml/min. Column temperature was
kept at 40uC. MS detection was in the positive ionization mode,
capillary voltage was set at 3 kV and fragmentor voltage was
varied from 120 V. N2 was used as drying gas at a flow rate of
13 liters/min and a temperature of 350uC. Nebulizer pressure was
set at 60 PSI. Quantifications were performed by monitoring in
selected ion monitoring mode the sodium adducts of the molecular
ions (AEA, m/z 370.3; 2-AG, m/z 401.3; HEA, m/z 334.3; 2-HG,
m/z 367.3).
Statistics
Endocannabinoid levels were analyzed by one-way ANOVA
where treatment (nicotine/controls) and time (16 h/34 h) were
treated as independent factors. Different brain regions were
analyzed separately. All behavioral experiments were analyzed
using one-way ANOVA except for body weight analysis during
dependence induction and withdrawal, which were performed by
two-way ANOVA where the within subjects variable was ‘‘time’’
(T=0, T=16, T=34 hours), and the between subjects variable
was ‘‘group’’ (Control, Nicotine). When appropriate, post hoc
comparisons were carried out by Newman-Keuls test.
Results
Blood nicotine and cotinine levels
Application of the nicotine patch resulted in elevated levels of
nicotine and cotinine in the blood.
Average nicotine levels at the middle (day 4) and at the end (day
7) of the dependence induction procedure were 691.0611.5 and
748.36134.3 mg/l, respectively. Levels of cotinine, the primary
metabolite of nicotine, appeared to increase from 12106174 mg/l
of day 4 to 15476109 mg/l of day 7, thus suggesting accumulation
of the metabolite in the blood. The relative standard deviations
resulting from the analysis in triplicate ranged from 1.3 to 2.2% for
run-to-run precision, and from 3.1 to 4.4% for day-to-day
precision. Blood nicotine and cotinine levels of nicotine naı ¨ve
animals were undetectable.
Experiment 1: Removal of chronically implanted
transdermal nicotine patches produces spontaneous
withdrawal
This experiment was performed to examine whether the
removal of chronically implanted transdermal nicotine patches is
able to cause somatic and affective symptoms of withdrawal. The
nicotine dependence induction procedure spontaneously produced
a substantial increase of overall somatic withdrawal signs
compared to controls ([F(1,10)=19.2, p,0.01], Figure 1A). In
URB597 Suppresses Symptoms of Nicotine Withdrawal
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control rats in all the examined dependent variables including
wet dog shakes/tremors [F(1,10)=20.9, p,0.01], teeth-chattering/
chews [F(1,10)=5.2, p,0.05] and gasps/writhes ([F(1,10)=16.2,
p,0.01], Table S1).
The occurrence of somatic withdrawal signs was accompanied
by secondary abstinence symptoms such as decreased locomotion
as reflected by reduction in the total distance travelled
([F(1,10)=4.7, p=0.05], Figure 1B) and increased immobility time
[F(1,10)=6.1, p,0.05]. Vertical locomotor activity was not affected
(rearings: [F(1,10)=0.0, NS], Table S2).
In the same groups of rats, anxiety-like behavior was then
evaluated in the EPM 34 h following patch removal. As shown in
Figure 1C, rats previously treated with nicotine spent significantly
less time exploring the open arms of the maze (percent open-arm
time, [F(1,10)=6.6, p,0.05]). Percentage of open-arm entries
resulted as a less reliable measure of anxiety-like behavior
[F(1,10)=0.8, NS]. Also, the number of closed-arm entries was
not changed at this time point ([F(1,10)=0.4, NS], Table S3).
Additional evidence for the occurrence of withdrawal following
chronic application of nicotine patches was provided by increased
weight gain during withdrawal. The dependence induction
procedure caused a progressive drop in body weight from day 1
(334.569.4 g) to day 7 (283.267.5 g) whereas control animals
maintained their normal weight trajectory during the 7-day period
(from 330.567.0 g to 336.268.6 g). ANOVA revealed an effect of
‘‘group’’ [F(1,10)=12.7, p,0.01] accompanied by effect of ‘‘day’’
[F(6,60)=34.0, p,0.001] and ‘‘group6day’’ interaction
[F(6,60)=35.3, p,0.001]. Following patch removal, the animals
previously exposed to nicotine exhibited an abrupt weight increase
at the two time points examined. According to ANOVA, a
significant effect of ‘‘group’’ [F(1,10)=16.0, p,0.01] and ‘‘time’’
[F(2,20)=10.4, p,0.001] was accompanied to ‘‘group6time’’
interaction ([F(2,20)=4.4, p,0.05], Figure 1D).
Experiment 2: Changes in tissue endocannabinoid levels
during acute and protracted nicotine withdrawal
Exposure to intoxicating doses of nicotine elicits marked
changes in AEA levels in various brain areas at the two time
points measured (Table 1). Specifically, statistically detectable
increases in AEA were observed in the amygdala [F(3,23)=4.4,
p,0.05], hypothalamus [F(3,23)=3.4, p,0.05] and prefrontal
cortex [F(3,23)=3.0, p=0.05]. In the hippocampus AEA levels
were decreased [F(3,23)=5.6, p,0.01], while no changes were
observed in the caudate-putamen [F(3,23)=0.7, NS] and nucleus
accumbens [F(3,23)=2.2, NS]. Post hoc analysis revealed changes of
AEA levels mostly at 34 h, where they were significantly increased
Figure 1. Spontaneous nicotine withdrawal measured after 7 days of nicotine exposure (5.2 mg/rat/day). Rats previously exposed to
nicotine showed (A) increased occurrence of overall withdrawal signs compared to non-exposed controls. Overall withdrawal signs were obtained for
each animal by accumulating the number of events belonging to different categories of somatic withdrawal manifestations (wet dog shakes/tremors,
gasp/writhes, chattering/chews) scored at 16 hours from nicotine discontinuation. Nicotine exposed rats also showed: (B) decreased distance (cm)
traveled in the open field at the 16-hour time point; (C) reduced percentage (%) in open arms time measured at 34 hours from nicotine patch
removal, and (D) rapid body weight gain (g). Values represent the mean (6SEM) of N=6 subjects per group. In A, B and C, *p,0.05, **p,0.01
difference vs. control. In D, **p,0.01, ***p,0.001 difference vs. nicotine group at T=0 h.
doi:10.1371/journal.pone.0028142.g001
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to increase was observed in the prefrontal cortex (p=0.09). In the
hippocampus AEA was decreased only at 16 h (p,0.05).
Variation in 2-AG levels were much less pronounced (Table 2).
Overall ANOVA revealed a significant alteration in 2-AG values in
the hippocampus [F(3,23)=6.9, p,0.01]. However, such difference
was due to changes in 2-AG levels at 34 h compared to 16 h and
was not the result of nicotine intoxication. A trend toward 2-AG
increase in the amydgala [F(3,23)=2.6, p=0.08] was also noted.
No differences were detected in the hypothalamus [F(3,23)=1.0,
NS]; nucleus accumbens [F(3,23)=0.4, NS]; prefrontal cortex
[F(3,23)=0.2, NS] and caudate-putamen [F(3,23)=1.5, NS].
Experiment 3: URB597 did not alter somatic withdrawal
signs of nicotine abstinence or locomotor activity and
withdrawal-induced weight gain
Overall ANOVA revealed that 7-day exposure to transdermal
nicotine patches induced a significant ([F(3,28)=8.0, p,0.01])
exacerbation of spontaneous withdrawal after 16 h from nicotine
patch removal. As shown by post hoc tests, treatment with URB597
failed to decrease total abstinence score (Figure 2A).
Analysis of individual somatic signs showed a significant overall
increase in the category chatter/chews [F(3,28)=3.0, p,0.05]. Post
hoc analysis revealed a significant difference (p,0.05, Figure 2C)
between naı ¨ve nicotine controls and rats exposed to nicotine and
treated with URB597 vehicle. The occurrence of wet dog shakes/
tremors ([F(3,28)=1.2, NS], Figure 2A), gasp/writhes ([F(3,28)=2.0,
NS], Figure 2D) and yawns ([F(3,28)=1.8, NS], Figure 2E) was
statistically unaffected and no difference was detected between the
different groups. A clear trend to increase of these signs following
nicotine cessation was always observed. A weak tendency of
URB597 in reducing gasp/writhes and yawns in nicotine-exposed
rats was noticed.
Locomotor activity in the open field was also analyzed
(Supplemental Table S4). Analysis of variance revealed a non-
significant overall difference for all the examined variables: distance
travelled [F(3,28)=1.5, NS], immobility time [F(3,28)=2.0, NS],
number of rearings [F(3,28)=0.4, NS]. According to results of
Experiment 1, a trend to a drop in locomotion was observed in
nicotine dependent animals compared to controls. URB597 showed
a slight non-significant trend to reverse the locomotor suppressive
effects associated to acute nicotine abstinence.
Body weight data at the time of patch removal (T=0) and 16 h
during withdrawal (T=16) are shown in Supplemental Table S5.
ANOVA revealed a main effectof ‘‘group’’ [F(3,28)=14.1, p,0.001]
as well as a main effect of ‘‘time’’ [F(1,28)=72.5, p,0.001], and
‘‘group6time’’ interaction [F(3,28)=3.1, p,0.05]. On post hoc
analysis, all three nicotine treated groups displayed body weight
gain regardless of URB597 treatment (p,0.001).
Experiment 4: URB597 reversed withdrawal-induced
anxiety in the EPM test
In agreement with Experiment 1, a potent anxiogenic-like effect
of nicotine withdrawal was detected at 34 h from patch removal,
which was reversed by URB597. ANOVA revealed a significant
overall effect in the percent of time spent in the open arms
[F(3,39)=4.4, p,0.01]. Post hoc analysis demonstrated that URB597
significantly reversed the effect of nicotine withdrawal at 0.1 mg/
kg (p,0.05) and a clear trend was observed at 0.3 mg/kg (p=0.07,
Figure 3A). The number of entries onto the open arms of the maze
was not affected [F(3.39)=0.4, NS]. Closed-arm entries, a measure
of locomotor activity, did not differ between control and URB597-
treated animals ([F(3,39)=1.5, NS], Table S6).
Additional nicotine naı ¨ve rats were used to test URB597 in the
EPM under basal conditions. Results evidenced that at doses that
reduced nicotine withdrawal-induced anxiety (0.1, 0.3 mg/kg),
URB597 did not affect elevated plus maze performance in
nicotine naı ¨ve animals. ANOVA revealed lack of significance for
all the dependent variables examined: percent of time spent in the
open arms [F(2,24)=0.3, NS]; percent of open arm entries
[F(2,24)=0.3, NS]; closed arm entries [F(2,24)=0.8, NS], Supple-
mental Table S7.
Experiment 5: URB597 prevented withdrawal-induced
enhancement of defensive burying
In the shock-probe defensive burying paradigm neither latency to
approach the probe for the first time nor the number of times rats
receiving shock from contacting the probe was modified by nicotine
abstinence, and as shown in Supplemental Table S8 ANOVA
revealed non-significant group differences ([F(3,27)=0.2, NS] and
([F(3,27)=0.7, NS], respectively). More importantly, ANOVA revealed
an overall difference in the time spent burying ([F(3,27)=5.4,p,0.01]).
Post hoc analysis showed an increase in burying time of nicotine-
exposed rats receiving vehicle compared to nicotine naı ¨ve animals
Table 1. Levels of the endocannabinoids anandamide (AEA,
pmol/g) in different brain structures during acute (16 h) and
protracted (34 h) nicotine withdrawal phases.
AEA (pmol/g) 16 h 34 h
Control Nicotine Control Nicotine
PFC 1.6960.2 1.5860.3 1.4460.2 2.3860.3
NAC 2.5160.5 2.0460.4 4.0961.3 2.5460.4
Amy 1.5960.2 2.2760.3 1.6260.2 2.6260.3*
CPU 1.9460.3 2.0860.1 1.7560.1 2.1460.2
Hippo 4.4760.6 3.0660.3* 3.4460.5
# 2.5560.2
Hypo 4.1360.4 4.7361.4 4.6960.8 8.3961.3*
Results showed that major changes occurred for AEA particularly in the
amygdala, the hypothalamus and the hippocampus. Values represent the mean
(6SEM) of subjects previously treated with nicotine compared to controls at
respective time points: *p,0.05.
#p,0.05,
## p,0.01, difference from control
group at 16 h time point;
+p,0.05, difference from nicotine group at 16 h time
point.
doi:10.1371/journal.pone.0028142.t001
Table 2. Levels of 2-arachydonyl-sn-glycerole (2-AG, pmol/
mg).
2-AG (pmol/mg) 16 h 34 h
Control Nicotine Control Nicotine
PFC 2.8760.4 2.9560.4 2.5960.5 3.0360.3
NAC 0.8260.2 0.8960.2 1.1060.4 0.8260.1
Amy 2.8860.4 3.8960.4 2.3060.7 4.3260.7
CPU 1.0260.1 1.1860.1 1.3560.1 1.2060.1
Hippo 2.7560.4 2.4560.2 1.4160.2
## 1.6260.2
+
Hypo 5.5761.0 6.5460.7 4.6461.6 6.5760.7
For detailed statistics, see Results. PFC, prefrontal cortex; NAC, nucleus
accumbens; Amy, amygdala; CPU, caudate putamen; Hippo, hippocampus;
Hypo, hypothalamus.
doi:10.1371/journal.pone.0028142.t002
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28142Figure 2. Spontaneous nicotine withdrawal measured 16 hours after nicotine patches (5.2 mg/rat/day) removal was not prevented
by administration of URB597 (0.0, 0.1 and 0.3 mg/kg, i.p.). (A) overall withdrawal symptoms, (B) wet dog shakes/tremors, (C) chattering/
chews, (D) gasp/writhes, (E) yawns. Values represent the mean (6SEM) of N=8 subjects per group. #p,0.05, ##p,0.01, difference vs. ‘‘C+0.0’’
group.
doi:10.1371/journal.pone.0028142.g002
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e28142(p,0.01). In animals exposed to nicotine but pre-treated with
URB597 0.1 (p,0.05) and 0.3 mg/kg (p,0.01), a significant reversal
nicotine withdrawal-induced burying was observed (Figure 3B).
Discussion
We found that a seven-day exposure to chronically implanted
transdermal nicotine patches produces sufficiently elevated levels
of blood nicotine and cotinine leading to a nicotine dependent
state characterized by spontaneous formation of a severe with-
drawal syndrome which includes somatic and affective compo-
nents. The present findings confirm previous studies in adolescent
rats where long-lasting effects on locomotor activity and anxiety-
like behaviors were described following chronic nicotine patch
delivery [13,45]. In addition, consistent with already published
work [11,12,46], we found that the peak in the manifestation of
somatic signs occurred 16 h after nicotine discontinuation. Among
categories of observed somatic withdrawal signs, results showed
statistically greater occurrence of teeth chattering/chews, gasp/
writhes and wet dog shakes/tremors. Withdrawal was accompa-
nied also by a drop in locomotor activity and a rapid body weight
gain following nicotine discontinuation. These measures further
reflect nicotine dependence severity. In humans, somatic mani-
festations of nicotine withdrawal are often accompanied by
depressed mood, aversive motivational state and increased anxiety,
whereas in laboratory animals withdrawal is associated to ele-
vations in brain reward threshold suggesting diminished interest
or pleasure in obtaining rewarding stimuli [5,19], a symptom
classically associated to depressed mood in humans. Previous
studies in rats also showed heightened anxiety in the auditory
startle reflex and social interaction tests in rats made dependent to
nicotine [47,48,49]. Consistent with these observation at 34 h
following the removal of nicotine patches, a time point that
corresponds to the protracted withdrawal phase, we observed
significant increase in anxiety-like symptoms both in the EPM and
in the defensive burying test.
Evidence suggests that nicotine addiction is linked to a mo-
dulation of the endocannabinoid signaling system in the brain. It
has been shown, for example, that chronic exposure to nicotine
leads to a decrease in AEA and 2-AG levels in midbrain, hip-
pocampus, striatum and cerebral cortex, whereas increased AEA
was detected in the limbic forebrain and brainstem [50].
Consistent with a role of the endocannabinoid system in nicotine
addiction recent studies also showed that inhibition of FAAH, the
major AEA degrading enzyme in the brain, interferes with
nicotine discriminative properties, blunts nicotine reward, prevents
its self-administration and reduces relapse [51,52,53]. Although
this important evidence implicates endocannabinoid mechanisms
in nicotine addiction, to our knowledge no data are currently
available on the role of such mechanisms in nicotine withdrawal.
To test the hypothesis that nicotine abstinence is associated with
alterations in endocannabinoid levels, in the present work the
contents of AEA and 2-AG were examined in brain structures
that are known to play a role in the regulation of negative
reinforcement and drug withdrawal symptoms and that express
elevated endocannabinoid activity as well as nicotinic acetylcho-
line receptors [22,32,54]. Such evaluation was carried out at two
time points to evaluate endocannabinoid fluctuations associated
with acute (16 h) and protracted (34 h) abstinence. The results
show an increase in AEA levels in the amygdala, hypothalamus
and prefrontal cortex, while reductions in AEA were detected in
the hippocampus. Importantly, most changes in AEA levels
occurred 34 h after nicotine exposure suggesting that anandamide
alterations is likely associated to protracted abstinence. Contrary
to AEA, 2-AG levels remained generally unaltered and a non-
significant trend to an increase was only observed in the amygdala.
In several studies including ours, it has been shown that somatic
manifestations of nicotine withdrawal peak at about 16 h from
nicotine exposure [11,12,46]. While, as observed here, at later
time points (i.e., 34 h) affective withdrawal signs such as anxiety
are predominant. Given that fluctuations in AEA levels have been
detected primarily at 34 h we hypothesize that this endocanna-
binoid modulates affective rather than somatic components of
withdrawal.
To explore the functional significance of AEA fluctuations in
nicotine withdrawal, we tested the effect of URB597, a potent
FAAH inhibitor, on both the somatic and the affective com-
ponents of withdrawal. The results show that URB597 does not
modify the expression of somatic withdrawal signs neither it affects
withdrawal-induced hypolocomotion or body weight gain. While
Figure 3. URB597 blocked nicotine withdrawal-induced anxi-
ety-like behavior, as assessed in the elevated plus-maze and in
the shock-probe defensive burying tests 34 hours after
nicotine discontinuation. (A) Animals previously exposed to
nicotine (N+0.0) showed significant reduction in percent (%) open
arm time compared to controls (C+0.0). URB597 returned % open arms
time to control levels. Values represent the mean (6SEM) of N=10–11
subjects per group. (B) Animals previously exposed to nicotine (N+0.0)
showed significant increase in burying time (seconds) compared to
controls (C+0.0). URB597 dose-dependently returned burying time to
control levels. Values represent the mean (6SEM) of N=7–8 subjects
per group; *p,0.05, **p,0.01 compared to nicotine exposed receiving
vehicle; #p,0.05, difference from non-nicotine exposed controls.
doi:10.1371/journal.pone.0028142.g003
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e28142this finding confirms our hypothesis that AEA is not involved in
the expression of body symptoms of nicotine withdrawal, on the
other hand, it does not match with a previous study which
examined the effects of D9-tetrahydrocannabinol (D
9-THC ) on the
incidence of nicotine withdrawal signs precipitated by mecamyl-
amine or naloxone in mice [15]. These authors showed a clear
protective effect of D
9-THC in reducing global score of somatic
signs. However, in our study we evaluated spontaneously
occurring acute withdrawal compared to these previous studies
where a more severe antagonist-precipitated abstinence was
studied [12,19]. Discrepancy may be also due to possible dif-
ferences in pharmacological properties of direct agonists at CB1
receptors compared to agents (i.e., FAAH inhibitors) which
activate these receptors following indirect pathways. Indeed, it
was shown that a systemic dose of 0.3 mg/kg that maximally
blocks FAAH, failed to mimic exogenous anandamide in pro-
ducing catalepsy, hypothermia and hyperphagia [34]. Moreover,
the same study by Balerio et al showed that the CB1 receptor
antagonist rimonabant failed to precipitate somatic signs in
nicotine dependent mice and, in a recent study that used FAAH
KO mice [16], somatic signs were 2-fold higher compared with
wild-type controls whereas the pharmacological inhibition of
FAAH by URB 597 produced no effect at moderate doses, thus
supporting our data. Altogether these findings suggest a complex
role of endogenous cannabinoid system in the physiological
control of the somatic manifestations of nicotine withdrawal but
clearly point to lack of protective properties by FAAH inhibitors .
The relevance of endocannabinoid mechanisms in the regula-
tion of affective signs of nicotine withdrawal was instead confirmed
by data showing that at 34 h treatment with URB597 prevented
the anxiogenic-like response associated with nicotine discontinu-
ation. Two different behavioral paradigms were used to assess
anxiety-like behavior: the EPM and the shock-probe defensive
burying tests. While the former is thought to reflect generalized
anxiety disorders [39], the latter commonly measures fear-like
responses generated by exposure to stressful environmental con-
ditions [40]. In these tests, anxiety associated to nicotine with-
drawal was revealed by a decreased percent of time spent
exploring the open arms of the EPM and by an increase in time
spent burying, respectively. URB597 treatment significantly
enhanced open arms exploration at the dose of 0.1 mg/kg while
markedly reduced the burying time in a dose-dependent manner.
These findings indicate that the anxiolytic effect of URB597 is
specific and does not depend upon drug-induced alterations in
locomotor behavior. In fact, if in the EPM generalized hypo-
locomotion may reduce exploration thus mimicking an anxio-
genic-like condition, in the defensive burying test hypolocomotion
would result in burying reduction that is a measure of anxiolytic
effects.
Our results are consistent with evidence that direct activation of
cannabinoid receptors by D
9-THC attenuates anxiogenic- but not
anxiolytic-like responses following acute nicotine administration.
[31]. Moreover, the findings extend previous observations
indicating that URB597 has particularly pronounced anxiolytic-
like effect if anxiety is associated with aversive conditions such as
stressful environments or drug withdrawal [36,55]. However, in
earlier reports anxiolytic-like effects of URB597 under basal
conditions were also described in mice [34,56] and rats [53,57].
Notably, in the EPM in rats this effect was found at doses higher
(1.0 mg/kg) than those found to be effective in withdrawing rats
(0.1 mg/kg) in our study [57]. Based on these findings it may be
argued that illumination of the testing arena, habituation of the
animals to the testing environment and their handling may
determine the anxiolytic efficacy of URB597. It is plausible, in
fact, that FAAH inhibition may result in anxiolytic action only
when given to animals exposed to highly stressful stimuli.
AEA is a local neuromodulator whose release is thought to be
regulated ‘‘on demand’’ by the activation of a variety of neuronal
substrates [54]. Upon its release, AEA is primarily degraded by
intracellular FAAH activity. Hence, blockade of this enzyme by
URB597 results in selective augmentation of AEA-mediated
transmission in those neural circuits in which this endocannabi-
noid is recruited. In the present study, we found that protracted
nicotine withdrawal is associated with increased anxiety and
augmented AEA levels. On the other hand, inhibition of FAAH by
URB597, leading to further increase in AEA mediated neuro-
transmission results in a reversal of anxiety-like responses asso-
ciated to nicotine withdrawal. These findings can be reconciled
based on the hypothesis that during withdrawal AEA is released to
restore physiological mechanisms temporarily disrupted by the
abrupt cessation of nicotine administration. However, if this
increase in AEA-mediated activity is not sufficient to counteract
the functional imbalance caused by sudden nicotine discontinu-
ation it is only after administration of URB597, and subsequent
accumulation of AEA, that is possible to observe an effect
on nicotine withdrawal. Consistent with the anxiolytic role of
endocannabinoids, current literature suggests that central admin-
istration of AEA, similar to URB597 results in marked anxiolytic-
like effects [58]. Similarly, the AEA transporter inhibitor AM404
was clearly shown to blunt mice escape reactions associated with
spontaneous opiate withdrawal [59].
Exogenous stimulation of nicotinic acetylcholine receptors or
lack of their activation, may be critical for fluctuations of en-
docannabinoid contents in the brain. The finding that alpha 7
nicotinic receptors initiate AEA formation in cortical neurons
strengthens this view [60]. In the present study, we found that the
amygdala is one of the areas where changes in endocannabinoid
level were most remarkable, and where AEA, and to a lesser extent
also 2-AG, showed an increase following nicotine discontinuation.
Given that the amygdala is involved in the regulation of negative
affect and emotions [61], this finding may indicate a role for AEA
in this area in the modulation of anxiety associated to nicotine
withdrawal.
Nicotine withdrawal is associated to a region-specific enhance-
ment of neuronal activity in the central nucleus of the amygdala
[62], and is accompanied by a selectively increase in adenylyl
cyclase activity in this brain area [63]. Since activation of CB1
receptors causes adenylyl cyclase inhibition, it may be speculated
that increased AEA content in the amygdala serves to counter-
balance withdrawal-induced stimulation of this intracellular
signaling pathway. A role of corticotrophin releasing hormone
(CRH), known to mediate endocrine, physiological and behavioral
responses to stress [64], is also possible. CRH is thought to play a
central role of the modulation of withdrawal from a variety of
drugs including alcohol [65], cocaine [66], cannabis [67] and
nicotine [68,69]. On the other hand, the endocannabinoid system
has been suggested to act as an anti-stress system [70,71]. Hence,
its activity during withdrawal may be increased in the attempt to
counteract for heightened CRH neurotransmission. During
nicotine withdrawal a significant increase in AEA levels were also
detected in the hypothalamus. Considering that elevated contents
in hypothalamic AEA may take part to the regulation of neuro-
endocrine response to stress [70], it may be possible that dys-
regulation of the endocannabinoid system in this area may take
part to alterations of hypothalamic-pituitary-adrenal axis activity
associated to nicotine withdrawal [72]. Finally, the finding that
AEA levels are decreased in hippocampus may be indicative of an
imbalance between the endocannabinoid and the cholinergic
URB597 Suppresses Symptoms of Nicotine Withdrawal
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e28142system in this area. Notably, an equilibrium between cholinergic
and endocannabinoid neurotransmission within the hippocampus
seems to be crucial for the homeostasis of emotional behavior and,
in turn, a misbalance, might result in a variety of emotional and
mood-related disorders [73].
In conclusion, we show here that a seven-day exposure to
chronically implanted transdermal nicotine patches induces
nicotine dependence characterized by spontaneous formation of
a severe withdrawal syndrome, which includes somatic and affec-
tive components. Withdrawal was associated to marked changes in
AEA levels in several brain areas, while 2-AG content was only
modestly affected. Previous studies demonstrated that FAAH
inhibition results in marked reduction in nicotine self-administra-
tion and relapse to drug seeking [50,51,52], while here we
demonstrated that the pharmacological inhibition of FAAH by
URB597 decreased anxiety associated to protracted nicotine
withdrawal. Together, these findings point to the possibility that
FAAH inhibition may represent an effective pharmacological
strategy for the treatment of nicotine addiction. Considering that
negative affective states associated with nicotine withdrawal is a
major concern for smoking cessation, this approach could result
particularly promising.
Supporting Information
Table S1 Somatic withdrawal signs observed 16 hours after
chronic nicotine discontinuation. Overall withdrawal signs as well
as single categories of the examined physical symptoms (teeth-
chattering/chews, gasps/writhes, shakes/tremors) were increased
in animals previously exposed to nicotine. Difference from
controls: *p,0.05, **p,0.01.
(DOC)
Table S2 Open field performance at 16 hours from nicotine
discontinuation. Nicotine exposed rats showed a decrease in
locomotor activity and an increase in immobility time. Difference
from controls: *p,0.05.
(DOC)
Table S3 Anxiety-like behavior measured by elevated plus maze
at 34 hours from nicotine discontinuation. Percent (%) open arms
was significantly decreased in nicotine exposed animals compared
to controls. Difference from controls: *p,0.05.
(DOC)
Table S4 Open field performance in nicotine exposed rats
treated with URB597 vehicle (N+0.0) or with 0.1 (N+0.1) and
0.3 mg/kg (N+0.3) of URB597. Difference from controls (C+0.0)
was not significant.
(DOC)
Table S5 Rats previously exposed to nicotine showed increased
weight gain compared with controls at 16 hours (T=16 h) from
patches removal (T=0 h). Nicotine naı ¨ve control (C+0.0), animals
exposed to nicotine and treated with URB597 vehicle (N+0.0) or
with 0.1 (N+0.1) and 0.3 mg/kg (N+0.3) of URB597. Difference
from Controls: ***p,0.001.
(DOC)
Table S6 Anxiety-related (percent open arm time and entries)
and locomotor-related (closed arms entries) variables on EPM
performance at 36 hours from nicotine discontinuation. Nicotine
naı ¨ve control (C+0.0), animals exposed to nicotine and treated
with URB597 vehicle (N+0.0) or with 0.1 (N+0.1) and 0.3 mg/kg
(N+0.3) of URB597. A non significant trend to reduction in %
open arm entries was observed in rats treated with nicotine and
URB597. *p,0.05, compared to nicotine exposed receiving
vehicle; #p,0.05, difference from non-nicotine exposed controls.
(DOC)
Table S7 EPM performance following URB597 treatment (0.0,
0.1, 0.3 mg/kg) in control non-withdrawing animals.
(DOC)
Table S8 Defensive burying performance scored 36 hours from
nicotine discontinuation. The number of probe approaches and
latency to bury was not different between groups. Nicotine naı ¨ve
control (C+0.0), animals exposed to nicotine and treated with
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